Marlborough, Mass.-based biotechnology company RXi Pharmaceuticals Corp. said it was no longer in compliance with a Nasdaq listing rule.
Specifically, the company's listed securities are below the stock exchange's minimum $2.5 million in stockholders' equity requirement.
The company has until Sept. 25 to regain compliance so it can remain listed on the Nasdaq Capital Market.
